MARC details
| 000 -LEADER |
|---|
| fixed length control field |
11018namaa22004331c 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20250223033259.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
240917b2023 |||a|||f m||| 001 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposite |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.99449 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
616.99449 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.19.04.M.Sc.2023.Es.E |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Esraa Ibraheem Mohamed Metwalli Sallam, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Efficiency of second line hormonal treatment in hormone receptor positive human epidermal growth factor receptor type 2 negative recurrent and or metastatic breast cancer / |
| Statement of responsibility, etc. |
By Esraa Ibraheem Mohamed Metwalli Sallam ; Supervised by Dr. Alfred Elias Namour , Dr. Abd El Hamid Mohamed Fouad , Dr. Alshimaa Zakaria Fathy |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
/ﻛﻔﺎءة اﻟﻌﻼج اﻟﮭﺮﻣﻮﻧﻲ ﻣﻦ اﻟﺨﻂ اﻟﺜﺎﻧﻲ ﻓﻲ ﺳﺮطﺎن اﻟﺜﺪي اﻟﻤﻨﺘﺸﺮ أو اﻟﻤﺮﺗﺠﻊ إﯾﺠﺎﺑﻲ اﻟﻤﺴﺘﻘﺒﻼت اﻟﮭﺮﻣﻮﻧﯿﺔ وﺳﻠﺒﻲ ﻋﺎﻣﻞ اﻟﻨﻤﻮ اﻟﺒﺸﺮي ﻣﻦ اﻟﻨﻮع اﻟﺜﺎﻧﻲ |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2023. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
136 pages |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.)-Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 105-134. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background:<br/> <br/>Metastatic breast cancer is incurable & there’s currently no standard of care so treatment goals are to prolong survival, delay disease progression, and enhance quality of life.<br/>Therefore choice of treatment should consider tumor characteristics to choose the most suitable drug to decrease disease burden with least side effect until evident unacceptable toxicity or disease progression. Since endocrine treatment (ET) with or without targeted therapy is less toxic than chemotherapy, it’s preferable to start with ET in luminal MBC& If a patient initially responds to an ET and then progresses, another ET may be used<br/>ET include; SERMs (Tamoxifen & Toremifene), AIs including; non-steroidal AIs (Anastrazole, Letrezole) & steroidal AIs (Exemestane), as well as SERDs (Fulvestrant).<br/><br/>Objective:<br/>Evaluating the efficacy & safety of second line hormonal treatment in hormone receptor positive, HER2 negative recurrent & or metastatic breast cancer.<br/><br/>-Patients and methods:<br/>This retrospective study included 116 female patients with hormone receptor positive, HER2 negative breast cancer, 29 of them had metastasis at initial presentation, 24 had isolated loco-regional recurrence and 63 developed distant recurrence after being treated as early or locally advanced breast cancer, all of cases failed on first line hormonal treatment & received second line hormonal treatment at medical oncology department of National cancer institute – Cairo University & started second line hormonal treatment in the period between January 2015 and December 2019 with follow up till June 2022.<br/><br/>-Results:<br/>Among 116 females we assessed efficacy of second line hormonal treatment with Fulvestrant (n=68), AI (n=44) which was sub-classified into (Exemestane (n=31) & Anastrazole (n=13)) & Tamoxifen (n=4).<br/>Results demonstrated Response rate (26.5% vs. 11.3%), clinical benefit rate (61.8% vs. 86.18%), median PFS (17.072 vs. 16.97 months) while median OS (147.2 vs. 105.09 months) for fulvestrant & AI respectively , while regarding type of AI, response rate was (9.7% vs. 15.4% ), clinical benefit rate (64.5% vs. 76.9%) , median PFS (18.06 vs. 14.05 months) while median OS (102.17 vs. 153.84 months) in exemestane & anastrozole respectively with tolerable side effects with all lines.<br/>Most common side effects were bony aches (28.3% with fulvestrant vs. 31.6 with AI) & fatigue (21.7% with fulvestrant vs. 15.8% with AI) (p; 0.001)<br/><br/>-Conclusion: <br/>There was no statistically significant difference found between different endocrinal treatments (Fulvestrant, AIs, tamoxifen) which were used as second line as regard response rate, clinical benefit rate, PFS & OS with tolerable side effects.<br/> |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
ﯾﻌد ﺳرطﺎن اﻟﺛدي أﻛﺛر اﻻﻣراض اﻟﺳرطﺎﻧﯾﺔ اﻧﺗﺷﺎرا ﻓﻲ اﻟﻧﺳﺎء ﻓﻲ اﻟوﻻﯾﺎت اﻟﻣﺗﺣدة وﺛﺎﻧﻲ أﻛﺛر اﻻورام ﺳﺑﺑﺎ<br/>ﻟﻠوﻓﺎة ﺑﻌد ﺳرطﺎن اﻟرﺋﺔ ﺳرطﺎن اﻟﺛدي اﯾﺟﺎﺑﻲ اﻟﻣﺳﺗﻘﺑﻼت اﻟﮭرﻣوﻧﯾﺔ وﺳﻠﺑﻲ ﻣﻌﺎﻣل ﻧﻣو اﻟﺑﺷرة ٢ھو أﻛﺛر ﻧوع ﻣن اﻟﺗﺻﻧﯾﻔﺎت اﻟﻔرﻋﯾﺔ<br/>اﻟﺟزﯾﺋﯾﺔ.<br/>ﺳرطﺎن اﻟﺛدي اﻟﻣﻧﺗﺷر ﻏﯾر ﻗﺎﺑل ﻟﻠﺷﻔﺎء اﻟﺗﺎم وﻟﻛن ھﻧﺎك ﺗﺣﺳن ﻓﻲ ﻣﻌدل اﻟﺑﻘﺎء ﻋﻠﻰ ﻗﯾد اﻟﺣﯾﺎة ﻣﻊ اﺳﺗﺧدام اﻟﻌﻼج اﻟﮭرﻣوﻧﻲ وﻟذﻟك ﯾﺗم اﺧﺗﯾﺎر اﻟﻌﻘﺎر اﻟﻣﻧﺎﺳب ﻟﺗﻘﻠﯾل ﺣدة اﻟﻣرض ﺑﺄﻗل اﺛﺎر ﺟﺎﻧﺑﯾﺔ ﻣﻣﻛﻧﺔ وذﻟك ﺣﺗﻰ ﺣدوث اﺛﺎر ﺟﺎﻧﺑﯾﺔ ﻏﯾر ﻣﺣﺗﻣﻠﺔ او ﺣدوث ﺗطور ﻓﻲ اﻟﻣرض وﻻن اﻟﻌﻼج اﻟﮭرﻣوﻧﻲ واﻟﻣوﺟﮫ اﻗل ﺳﻣﯾﺔ ﻣن اﻟﻌﻼج<br/>اﻟﻛﯾﻣﯾﺎﺋﻲ ﻟذا ﯾﻔﺿل ان ﯾﺑدأ ﺑﮫ<br/>اﻟﺳﯾدات اﻟﻼﺗﻲ ﺗطور ﻟدﯾﮭن اﻟﻣرض ﺑﻌد ٢١ﺷﮭر او أﻛﺛر ﻣن اﻟﻌﻼج اﻟﮭرﻣوﻧﻲ اﻟﻣﺳﺎﻋد او ﻣن ﺣدث ﻟﮭم اﻧﺗﺷﺎر ﺣدﯾﺛﺎ ﯾﺗم اﺳﺗﺧدام ﺧط اﻟﻌﻼج اﻟﮭرﻣوﻧﻲ اﻻول ﺑﺎﻟرﻏم م وﺟود ﻗﻠﺔ ﻣن اﻟﻣرﺿﻲ ﯾﻌﺎﻧﯾن ﻣن ﺛﺎﻧوﯾﺎت ﺷدﯾدة ف اﻻﺣﺷﺎء ﻓﻲ ﺻورة اﻋراض ﺗﻧﻔﺳﯾﺔ او ارﺗﻔﺎع ﻓﻲ اﻧزﯾﻣﺎت اﻟﻛﺑد وﺣﯾﻧﮭﺎ ﯾﺑدأ اﻟﻌﻼج اﻟﻛﯾﻣﺎوي ﻟﺗزﯾد ﻓرص<br/>اﻻﺳﺗﺟﺎﺑﺔ اﻟﺳرﯾﻌﺔ ﻟﻠﻣرض إذا ﺣدث ﺗطور ﻟﻠﻣرض ﻣﻊ ﺧط اﻟﻌﻼج اﻟﮭرﻣوﻧﻲ اﻻول ﺣﯾﻧﮭﺎ ﯾﺗم اﺳﺗﺧدام ﺧط اﻟﻌﻼج اﻟﺛﺎﻧﻲ<br/>ﻓﻲ ﺣﺎﻟﺔ ﻓﺷل اﻻﺳﺗﺟﺎﺑﺔ ﻟﻠﻌﻼج او اﻟﺗوﻗف ﻋﻧﮭﺎ ﺣﯾﻧﮭﺎ ﯾﺟب ﻣﻌرﻓﺔ: ﻧﺳﺑﺔ ﻣﺳﺗﻘﺑﻼت اﻻﺳﺗروﺟﯾن ﻓﻲ اﻻﻧﺳﺟﺔ ﻣدة اﻻﺳﺗﺟﺎﺑﺔ ﻟﺧط اﻟﻌﻼج اﻻول<br/>ﺗﺣﻣل اﻟﻣرﯾض ﻟﺧط اﻟﻌﻼج اﻻول ووﺟود او ﻋدم وﺟودة ﺛﺎﻧوﯾﺎت ﻋﻧﯾﻔﺔ ﻓﻲ اﻻﺣﺷﺎء<br/>وذﻟك ﻟﯾﺗم ﺗﺣدﯾد إذا ﻛﺎن اﻟﻣرﯾض ﻓﻲ ﺣﺎﺟﺔ ﻟﻠﻌﻼج اﻟﻛﯾﻣﯾﺎﺋﻲ ﻟﻠﺣﺻول ﻋﻠﻰ اﺳﺗﺟﺎﺑﺔ أﺳرع ام اﻟﺗﻐﯾر ﻟﺧط اﻟﻌﻼج<br/>اﻟﮭرﻣوﻧﻲ اﻟﺛﺎﻧﻲ<br/>اﻟﻐرض ﻣن ھذه اﻟرﺳﺎﻟﺔ ھو ﺗﻘﯾﯾم ﻛﻔﺎءة اﻟﻌﻼج اﻟﮭرﻣوﻧﻲ ﻛﺧط ﻋﻼج ﺛﺎﻧﻲ ﻓﻲ ﺳرطﺎن اﻟﺛدي اﯾﺟﺎﺑﻲ اﻟﻣﺳﺗﻘﺑﻼت اﻟﮭرﻣوﻧﯾﺔ وﺳﻠﺑﻲ ﻣﻌﺎﻣل ﻧﻣو اﻟﺑﺷرة اﻟﻣﻧﺗﺷر او اﻟﻣرﺗﺟﻊ اﻟذﯾن ﺑدأوا اﻟﻌﻼج اﻟﮭرﻣوﻧﻲ ﻓﻲ اﻟﻔﺗرة ﻣن ﯾﻧﺎﯾر ﺣﺗﻲ دﯾﺳﻣﺑر ٩١٠٢ ﻣﻊ ﻣﺗﺎﺑﻌﺔ اﻟﺣﺎﻻت ﺣﺗﻲ ﯾوﻧﯾو ٢٢٠٢ ﻛﺗﺟرﺑﺔ ﻗﺳم طب اﻻورام – اﻟﻣﻌﮭد اﻟﻘوﻣﻲ<br/>ﻟﻸورام_ﺟﺎﻣﻌﺔ اﻟﻘﺎھرة<br/>ھذه اﻟدراﺳﺔ اﺣﺗوت ﻋﻠﻲ ٦١١ اﻣرأة ﺗﻌﺎﻧﻲ ﻣن ﺳرطﺎن اﻟﺛدي اﯾﺟﺎﺑﻲ اﻟﻣﺳﺗﻘﺑﻼت اﻟﮭرﻣوﻧﯾﺔ وﺳﻠﺑﻲ ﻣﻌﺎﻣل ﻧﻣو<br/> <br/>و ٤٢ ﺣﺎﻟﺔ ﻛﺎﻧت ﺣﺎﻟﺔ<br/> <br/>ﺣﺎﻟﺔ ﻛﺎﻧت ﺗﻌﺎﻧﻲ ﻣن ﺳرطﺎن ﻣﻧﺗﺷر ﻣﻧذ اﻟﺑداﯾﺔ<br/> <br/>اﻟﺑﺷرة اﻟﻣﻧﺗﺷر او اﻟﻣرﺗﺟﻊ: ٩٢<br/> <br/>ﻣرﺗﺟﻌﺔ و ٣٦ ﻋﺎﻧت ﻣن اﻻﻧﺗﺷﺎر ﺑﻌد ﺗﺷﺧﯾﺻﮭﺎ وﻋﻼﺟﮭﺎ ﻛﺳرطﺎن ﺛدي ﻣﺑﻛر ﺟﻣﯾﻌﮭم ﻓﻘدوا اﻻﺳﺗﺟﺎﺑﺔ ﻟﻠﻌﻼج<br/>اﻟﮭرﻣوﻧﻲ ﻛﺧط أول وﺗﻠﻘوا ﻋﻼج ھرﻣوﻧﻲ آﺧر ﻛﺧط ﺛﺎﻧﻲ.<br/>واوﺿﺣت ﻧﺗﺎﺋﺞ اﺳﺗﺧدام اﻟﻌﻼج اﻟﮭرﻣوﻧﻲ ﻛﺧط ﻋﻼﺟﻲ ﺛﺎﻧﻲ ﺑﻌﻘﺎر ﻓوﻟﻔﺳﺗراﻧت (fulvestrant) ﻗد ﺣﻘق<br/>ﻣﻌدل اﺳﺗﺟﺎﺑﺔ ٥,٦٢% ، ﻣﻌدل اﺳﺗﻔﺎدة اﻛﻠﯾﻧﯾﻛﯾﺔ ٨,٣٣% ﻛﻣﺎ ﻧﺗﺞ ﻋﻧﮫ ﻣﺗوﺳط ﺑﻘﺎء ﺧﺎﻟﯾﺎ ﻣن اﻟﻣرض ﯾﺻل اﻟﻲ,<br/> <br/>٣ ﺳﻧوات ٩,٩١% و ﻣﻌدل ﺑﻘﺎء ﻋﻠﻲ ﻗﯾد اﻟﺣﯾﺎة ﯾﺻل اﻟﻲ<br/> <br/>ﺧﻼل<br/> <br/>٧١,٢٧٠ ﺷﮭرا ﺑﻣﻌدل ﺑﻘﺎء ﺧﺎﻟﻲ ﻣن اﻟﻣرض<br/> <br/>ﺑﯾﻧﻣﺎ اﻟﻌﻼج ﺑﻣﺛﺑطﺎت اﻧزﯾم اﻻروﻣﺎﺗﯾز<br/> <br/>٥ ﺳﻧوات٤,٠٩%<br/> <br/>٢,٧٤١ ﺷﮭرا ﺑﻣﻌدل ﺑﻘﺎء ﻋﺎم ﻋﻠﻲ ﻗﯾد اﻟﺣﯾﺎة ﺧﻼل<br/> <br/>inhibitors) (AI ﺣﻘق ﻣﻌدل اﺳﺗﺟﺎﺑﺔ ٣,١١% ، ﻣﻌدل اﺳﺗﻔﺎدة اﻛﻠﯾﻧﯾﻛﯾﺔ ٨١,٦٨ % ﻛﻣﺎ ﻧﺗﺞ ﻋﻧﮫ ﻣﺗوﺳط ﺑﻘﺎء<br/> <br/>ﺳﻧوات ٤,٩١% و ﻣﻌدل<br/> <br/>٧٩,٦١ ﺷﮭرا ﺑﻣﻌدل ﺑﻘﺎء ﺧﺎﻟﻲ ﻣن اﻟﻣرض ﺧﻼل ٣<br/> <br/>ﺧﺎﻟﯾﺎ ﻣن اﻟﻣرض ﯾﺻل اﻟﻲ<br/> <br/>ﺳﻧوات١٨% .<br/> <br/>ﺷﮭرا ﺑﻣﻌدل ﺑﻘﺎء ﻋﺎم ﻋﻠﻲ ﻗﯾد اﻟﺣﯾﺎة ﺧﻼل ٥<br/> <br/>ﺑﻘﺎء ﻋﻠﻲ ﻗﯾد اﻟﺣﯾﺎة ﯾﺻل اﻟﻲ ٩٠,٥٠١<br/> ﻧﺗﺎﺋﺞ اﻟرﺳﺎﻟﺔ ﻟم ﺗوﺿﺢ ﻓرﻗﺎ واﺿﺣﺎ ﺑﯾن ﺧطوط اﻟﻌﻼج اﻟﮭرﻣوﻧﻲ اﻟﻣﺳﺗﺧدﻣﺔ وﻛذﻟك ﺗﺑﯾن وﺟود اﺛﺎر ﺟﺎﻧﺑﯾﺔ<br/>اﻛﺛرھﺎ اﻵم اﻟﻌظﺎم واﻹرھﺎق وﻟﻛن ﺟﻣﯾﻊ اﻻﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ ﻛﺎﻧت ﻣﺣﺗﻣﻠﺔ.<br/> |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Breast cancer |
| Source of heading or term |
qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Second line |
| -- |
metastatic |
| -- |
recurrent |
| -- |
Aromatase inhibitors |
| -- |
Endocrine therapy |
| -- |
Fulvestrant |
| -- |
luminal |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Alfred Elias Namour |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Abd El Hamid Mohamed Fouad |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Alshimaa Zakaria Fathy |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2023 |
| Supervisory body |
Alfred Elias Namour |
| -- |
Abd El Hamid Mohamed Fouad |
| -- |
Alshimaa Zakaria Fathy |
| Universities |
Cairo University |
| Faculties |
National cancer institute |
| Department |
Department of Medical Oncology |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| Reviser Names |
Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |
